

## INDEX

---

*Note: Entries followed by “f” indicate figures;  
“t” indicate tables.*

- AAP/AAFP guidelines, 48-54, 71-72, 81-82, 141-146, 157-161, 244
  - for diagnoses, 48-54, 49t, 52t-53t
  - overviews of, 244
  - for therapies, 141-146, 144t-146t, 157-161, 158t-159t
    - first-line, 141-146, 144t-146t
    - second-line and third-line, 157-161, 158t-159t
  - for tympanocentesis, 71-72, 73t-76t, 81-82
- Abbreviations and terms, 12-13, 14t-16t. *See also under individual topics.*
  - antibiotic failure, 14t
  - AOM, 11-17, 14t-16t
  - CDC, 14t
  - DRSP, 15t
  - early onset AOM, 12, 14t
  - FDA, 15t
  - MEE, 11-17, 15t
  - Moraxella catarrhalis*, 15t
  - ntHi, 15t
  - OME, 11, 15t
  - otitis-prone children, 13, 15t
  - PCV-7, 13, 17
  - persistent AOM, 12, 14t
  - recurrent AOM, 12, 14t
  - refractory AOM, 12, 14t
  - TM, 11
- Abscesses, 224
- Acquired immunodeficiency syndrome (AIDS), 152
- Active immunization, 235-244
  - bacterial (pneumococcal), 235-236, 238-244
  - viral, 235-236
- Acute mastoiditis, 224
- Acute otitis media (AOM) diagnoses and management topics.
  - See also under individual topics.*
  - antibiotic therapies, 85-203
    - first-line, 141-157
    - second-line and third-line, 157-203
    - selection fundamentals, 85-141
  - case presentations, 251-256
  - clinical trials. *See* Clinical trials, PCV-7.
  - complications, 215-227
  - diagnoses, 47-70
  - epidemiology, 19-32

Acute otitis media (AOM) diagnoses and management topics  
(*continued*)  
fundamental concepts, 11-18  
pathology, immunology, and natural history, 33-46  
prevention, 227-251  
reference resources for. *See* Reference resources.  
tympanocentesis, 71-84  
tympanostomy tubes, 203-214  
Acute petrositis, 222  
Adenoidectomy, 228-229  
Adenoviruses, 39t  
Adhesive otitis, 220  
Adjunctive diagnostic tools, 55  
Adverse effects, antibiotic therapies, 112-119, 114t-117t  
Afebrile child with AOM and pneumonia development  
(case presentations), 251  
Agents and classes, drug. *See* Drug names, generic and trade.  
Age-related factors, 19-21, 21f-22f  
AIDS (acquired immunodeficiency syndrome), 152  
Alden-Senturia traps, 74t, 77  
Allergies, 38-40, 144t-145t, 151-153, 152f  
antibiotic, 151-153, 152f  
immune responses and, 38-40  
penicillin, 144t-145t  
American Academy of Pediatrics/American Academy of Family  
Physicians (AAP/AAFP) guidelines, 48-54, 49t, 52t-53t, 71-72,  
73t-76t, 81-82, 244  
for diagnoses, 48-54, 49t, 52t-53t  
overviews of, 244  
for therapies, 141-146, 144t-146t, 157-161, 158t-159t  
first-line, 141-146, 144t-146t  
second-line and third-line, 157-161, 158t-159t  
Amoxicillin, 92t, 101t, 114t, 127f, 143-150, 144t-145t, 148f-149f,  
169, 172t, 182t, 185, 232-233, 246t-247t, 252-254  
Amoxicillin/clavulanate, 92t, 101t, 114t, 127f, 144t-145t,  
157-161, 170-174, 172t, 177, 178t, 185-189, 191-192,  
246t-247t, 254-255  
Amoxil, 92t. *See also* Amoxicillin.  
Anaphylaxis, 151  
Anatomy, 33, 215, 217f  
of ETs, 33  
of local and contiguous structures, 215, 217f  
Antibiotic therapies, 85-203. *See also under specific classes  
and agents.*  
broad-spectrum intravenous antibiotics, 222  
chemoprophylaxis, 233-234. *See also* Chemoprophylaxis.

Antibiotic therapies (*continued*)  
clinical trials, PCV-7, 86-90, 161-169  
Block study (rural Kentucky), 86-89, 88f, 164, 176-177  
Casey and Pichichero study (Rochester, NY), 86, 89, 163-164  
Caspary study (Norfolk, VA), 86, 89-90  
Eskola study (Finland), 86-87, 163  
Kaiser-Permanente study, 162-163  
overviews of, 86, 161-162  
Tennessee Medicaid program study, 163-164  
drug names. *See* Drug names, generic and trade.  
failure of, 14t, 15  
first-line therapies, 141-156  
AAP/AAFP guidelines for, 141-146, 144t-146t  
antibiotic allergies and, 151-153, 152f  
dosing rationales for, 146-147, 148f-149f  
immune functions and, 153-154  
overviews of, 141-142  
penicillin allergies and, 144t-145t  
reference resources for, 154-156  
resistant AOM risks and, 142t  
immunization, 237-245. *See also* Immunization; Prevention.  
bacterial (pneumococcal), 237-245  
viral, 234-237  
outcomes of, 44t-45t, 54-55  
second-line and third-line therapies, 157-202  
AAP/AAFP guidelines for, 157-161, 158t-159t  
efficacy measures and predictions for, 177-189, 178t, 182t-183t  
options for, 157-161, 158t-159t  
overviews of, 157, 158t-159t  
patient compliance and, 189-190  
PCV-7, 161-169, 165f, 168t. *See also* PCV-7 (pneumococcal  
conjugate vaccine).  
pharmacokinetics and pharmacodynamics for, 177-179, 178t  
reference resources for, 197-202  
refractory/recurrent AOM and, 192-199  
safety factors for, 189-190  
second-line therapies, 169-190  
selection rationale for, 169  
success determination for, 170-174, 172t-174t  
third-line therapies, 190-199  
treatment-resistant pathogens and, 175-176  
tympanocentesis and, 196. *See also* Tympanocentesis.  
selection fundamentals, 85-141  
additional considerations, 126-132  
adverse effects, 112-119, 114t-117t  
algorithms for, 126, 127f  
AOM bacteriology and, 95-112. *See also* Bacteriology.

- Antibiotic therapies, selection fundamentals (*continued*)
- choices for, 91-94, 92t-94t, 126, 127f
  - cost-related factors of, 113, 114t-117t
  - dosing frequencies and durations, 91-93, 92t-93t, 114t-117t, 118-126, 121t
  - follow-up care and, 129-131, 130f
  - otorrhea management and, 128
  - overprescription considerations, 131-133
  - overviews of, 85
  - palatability, 114t-117t, 118
  - patient compliance, 112-119
  - PCV-7, 86-90. *See also* PCV-7 (pneumococcal conjugate vaccine).
  - reference resources for, 133-140
  - safety factors, 112-113
  - susceptibility break points, 101t-102t
  - vaccine serotype replacement, 90-91
  - viruses and, 131
  - targeted, 71
  - vs tympanocentesis, 73t. *See also* Tympanocentesis.
  - vs tympanostomy tubes, 213. *See also* Tympanostomy tubes.
- AOM (acute otitis media) diagnoses and management topics.
- See also under individual topics.*
  - antibiotic therapies, 85-203
    - first-line, 141-157
    - second-line and third-line, 157-203
    - selection fundamentals, 85-141
  - case presentations, 251-256
  - clinical trials. *See* Clinical trials, PCV-7.
  - complications, 215-227
  - diagnoses, 47-70
  - epidemiology, 19-32
  - fundamental concepts, 11-18
  - pathology, immunology, and natural history, 33-46
  - prevention, 227-251
  - reference resources for. *See* Reference resources.
  - tympanocentesis, 71-84
  - tympanostomy tubes, 203-214
- Arthralgia, 151
- Atelectasis, 211
- Augmentin and Augmentin ES-500, 92t. *See also* Amoxicillin/clavulanate.
- Axetil. *See* Cefuroxime axetil.
- Azithromycin, 93t, 102t, 116t, 145t, 151, 173t, 178t, 183t, 187, 246t-247t, 254-255
- B strain, 235-236
- Bacterial (pneumococcal) immunization, 237-245, 239f, 240t-241t, 243t. *See also* Immunization.
- active, 238-245
  - overviews of, 237-238, 239f, 240t-241t
  - passive, 238
- Bacterial polysaccharide immunoglobulin (BPIG), 238
- Bacteriology, 95-112
- age risk factors and, 108
  - antibiotic resistance mechanisms, 96-97
  - daycare-related risk factors and, 108-111
  - geographic location risk factors and, 108, 109f, 110t
  - overviews of, 95
  - pathogens, 97-103
    - pathogen-antibiotic susceptibilities measures, 97-98, 98f, 100t-101t
    - prevalence of, 99-103
    - of recurrent AOM, 103-107, 106t-107t
- Bactrim. *See* Septra/Bactrim.
- Biaxin, 93t. *See also* Clarithromycin.
- Bilateral purulent conjunctivitis with AOM (case presentation), 252-253
- Block study (rural Kentucky), 86-89, 88f, 164, 176-177
- Blocked tube reopening, 206
- Bottle propping, 229
- Bottle-feeding vs breast feeding risk factors, 27, 231
- BPIG (bacterial polysaccharide immunoglobulin), 238
- Brain abscesses, 224
- Breast-feeding vs bottle feeding, 27, 231
- Broad-spectrum intravenous antibiotics, 222
- Bulging AOM (acute otitis media), color plate 1
- CAIV (cold-adapted (intranasal) influenza vaccine), 236-237
- Candida albicans*, 207-208
- Case presentations, 251-256
- bilateral purulent conjunctivitis with AOM, 252-253
  - lymphadenitis and impetigo development in child with AOM, 253-254
  - overviews of, 251
  - persistent AOM, 252-255
    - in fully vaccinated child during azithromycin treatment, 255
    - in immunized child receiving amoxicillin and with high fever and moderate leukocytosis, 252
  - persistent vomiting and diarrhea with AOM during amoxicillin treatment, 254-255
  - pneumonia development in afebrile child with AOM, 251
- Casey and Pichichero study (Rochester, NY), 86, 89, 163-164

Caspary study (Norfolk, VA), 86, 89-90  
 Causative organism-based predictors, 57-58  
 CDC (Centers for Disease Control and Prevention), 15t, 72  
 CDT Aspirator, color plate 2, 77  
 Ceclor, 92t. *See also* Cefaclor.  
 Cedax, 93t. *See also* Cefitibuten.  
 Cefaclor, 92t, 114t, 172t, 182t  
 Cefaclor/loracarbef, 101t  
 Cefdinir, 93t, 101t, 115t, 127f, 144t, 151, 158-160, 170-177, 173t, 178t, 182t, 187-189, 191-192, 244, 246t-247t, 254  
 Cefixime, 93t, 102t, 115t, 161, 173t, 182t, 185-186, 244, 246t-247t  
 Cefpodoxime, 102t, 118-119, 127f, 144t, 145t, 151, 160-161, 173t, 177, 178t, 182t, 183t, 187-189, 191-192  
 Cefpodoxime proxetil, 93t, 115t, 244, 246t-247t  
 Cefprozil, 92t, 101t, 115t, 151, 173t, 178t, 182t, 246t-247t, 254  
 Cefitibuten, 93t, 102t, 115t, 173t, 183t  
 Ceftin, 92t. *See also* Cefuroxime axetil.  
 Ceftriaxone, 71, 93t, 102t, 115t, 144t, 173t, 178t, 187-189, 191-192, 203, 252  
 Cefuroxime, 118-119, 144t, 173t, 178t, 182t, 189-190, 244  
 Cefuroxime axetil, 92t, 101t, 115t, 244, 246t-247t  
 Cefzil, 92t. *See also* Cefprozil.  
 Centers for Disease Control and Prevention (CDC), 15t, 72  
 Cephalosporins, 92t-93t, 101t-102t, 114t-115t, 151, 172t-173t, 182t-183t, 185, 254  
   second-generation, 92t, 101t, 114t-115t, 172t-173t, 182t  
   third-generation, 92t, 101t-102t, 115t, 173t, 182t-183t  
 Chemoprophylaxis, 232-234  
   antibiotic, 232-233  
   overviews of, 233  
   xylitol, 233-234  
 Chemotherapy, 152  
 Child restraints, 74t  
*Chlamydiae pneumoniae*, 99, 103, 146, 158t  
*Chlamydiae trachomatis*, 103  
 Choanal atresia, 23t  
 Cholesteatoma, 34, 204, 210-211  
 Chronic corticosteroid therapy, 152  
 Chronic TM (tympanic membrane) perforation, 82  
 Cigarette smoke risk factors, 24-25, 36, 231-232  
 Ciprofloxacin, 101t  
 Clarithromycin, 93t, 102t, 116t, 119, 145t, 173t, 183t, 254-255  
 Classes and agents, drug. *See* Drug names, generic and trade.  
 Clavulanate. *See* Amoxicillin/clavulanate.  
 Cleft palate, 23t, 204  
 Cleocin, 93t. *See also* Clindamycin.  
 Clindamycin, 93t, 102t, 116t, 145t, 174t, 209  
 Clinical and Laboratory Standards Institute (CLSI), 97  
 Clinical failures, expected, 246t-247t  
 Clinical trials, PCV-7, 86-90, 161-169, 176-177  
   Block study (rural Kentucky), 86-89, 88f, 164, 176-177  
   Casey and Pichichero study (Rochester, NY), 86, 89, 163-164  
   Caspary study (Norfolk, VA), 86, 89-90  
   Eskola study (Finland), 86-87, 163  
   Kaiser-Permanente study, 162-163  
   overviews of, 86, 161-162  
   Tennessee Medicaid program study, 163-164  
*Clostridium difficile*, 112-113  
 Cold-adapted (intranasal) influenza vaccine (CAIV), 236-237  
 Combination antibiotic therapies, 94t, 102t, 116t  
 Compliance-related factors, 112-119, 189-190  
 Complications, 215-227  
   anatomy fundamentals (local and contiguous structures) and, 215, 217f  
   expected complications, 215-221, 217f  
   conductive hearing loss, 217f, 218-220  
   OME, 215, 217f, 218-220  
   overviews of, 215, 217f, 218  
   persistent/recurrent AOM, 215, 217f  
   outcomes algorithms for, 216f  
   overviews of, 215, 216f-217f  
   reference resources for, 225-226  
   of tympanostomy tubes, 209-211. *See also* Tympanostomy tubes.  
   uncommon less serious complications, 217f, 220  
     adhesive otitis, 220  
     TM perforation, acute vs chronic, 217f, 220  
     tympanosclerosis, 217f, 220  
     tympanostomy tube extrusion, 217f, 220  
   uncommon serious complications, 217f, 221-225  
     acute petrositis, 222  
     brain abscesses, 224  
     cholesteatoma, 217f, 221, 224  
     dural sinus thrombosis, 224  
     epidural abscesses, 224  
     extradural abscesses, 224  
     facial nerve paralysis, 217f, 221-222, 225  
     labyrinthitis, 222  
     mastoiditis, 217f, 221-224  
     meningitis, 217f, 221  
     middle ear ossicles, 217f, 225  
     ossicle discontinuity, 217f  
     otitic hydrocephalus, 221  
     overviews of, 221-222  
     permanent profound sensorineural hearing loss, 217f, 222

Complications, uncommon serious complications (*continued*)  
sigmoid sinus thrombosis, 221  
subdural empyema, 224  
temporal bone osteitis (Gradenigo's syndrome), 221  
vertigo, 217f, 221, 224

Concomitant viral infections, 158t

Conductive hearing loss, 217f, 218-220

Contiguous and local structures, anatomy of, 215, 217f

Corticosteroid therapy, chronic, 152

Cost-related factors, 113, 114t-117t, 211  
of antibiotic therapies, 113, 114t-117t  
for tympanostomy tubes, 211

CRM197, 161

Culture procedures, 77-81

Day care-related risk factors, 28

Definitions, 12-13, 14t-16t. *See also* Terms and abbreviations.

Diagnoses, 47-71  
AAP/AAFP guidelines for, 48-54, 49t, 52t-53t  
adjunctive tools for, 55  
ancillary instruments and, 67  
common pitfalls of, 65-67  
critical elements of, 55-56  
MEE and, 53t-54t  
overviews of, 47-48  
pneumatic otoscopy for, 58-65, 59t, 60f-64f  
equipment for, 59t, 64f  
lighting for, 65  
overviews of, 58, 65  
procedures for, 60f-63f  
results interpretation for, 60f-63f  
of post-antibiotic AOM, 54  
predictors, 57-58  
causative organism-based, 57-58  
URTI symptom-based, 57  
reference resources for, 69-70  
symptoms, 56-57

Diarrhea and vomiting with AOM during amoxicillin treatment  
(case presentations), 254-255

Discontinuity, ossicles, 217f

Dosing frequencies and durations, 91-93, 92t-93t, 114t-117t,  
118-126, 121t. *See also* Antibiotic therapies.

Down syndrome, 23t, 24, 204, 220

DRSP (drug-resistant *Streptococcus pneumoniae*), 73

Drug names, generic and trade. *See also under individual topics.*  
amoxicillin, 92t, 101t, 114t, 127f, 143-150, 144t-145t, 148f-  
149f, 169, 172t, 182t, 185, 232-233, 246t-247t, 252-254

Drug names, generic and trade (*continued*)  
amoxicillin/clavulanate, 92t, 101t, 114t, 127f, 144t-145t,  
157-161, 170-174, 172t, 177, 178t, 185-186, 187-189,  
191-192, 246t-247t, 254-255  
Amoxil, 92t. *See also* Amoxicillin.

Augmentin and Augmentin ES-500, 92t. *See also* Amoxicillin/  
clavulanate.

azithromycin, 93t, 102t, 116t, 145t, 151, 173t, 178t, 183t, 187,  
246t-247t, 254-255

Bactrim. *See* Septra/Bactrim.

Biaxin, 93t. *See also* Clarithromycin.

Ceclor, 92t. *See also* Cefaclor.

Cedax, 93t. *See also* Ceftributen.

cefaclor, 92t, 114t, 172t, 182t  
cefaclor/loracarbef, 101t  
cefixime, 93t, 102t, 115t, 161, 173t, 182t, 185-186, 244,  
246t-247t  
cefpodoxime, 102t, 118-119, 127f, 144t, 145t, 151, 160-161,  
173t, 177, 178t, 182t, 183t, 187-189, 191-192  
cefpodoxime proxetil, 93t, 115t, 244, 246t-247t  
cefprozil, 92t, 101t, 115t, 151, 173t, 178t, 182t, 246t-247t, 254  
ceftibuten, 93t, 102t, 115t, 173t, 183t  
Ceftin, 92t. *See also* Cefuroxime axetil.

ceftriaxone, 71, 93t, 102t, 115t, 144t, 173t, 178t, 187-189,  
191-192, 203, 252  
cefuroxime axetil, 92t, 101t, 115t, 244, 246t-247t

Cefzil, 92t. *See also* Cefprozil.

cephalosporins, 92t-93t, 101t-102t, 114t-115t, 151, 172t-173t,  
182t-183t, 185, 254  
second-generation, 92t, 101t, 114t-115t, 172t-173t, 182t  
third-generation, 92t, 101t-102t, 115t, 173t, 182t-183t

ciprofloxacin, 101t  
clarithromycin, 93t, 102t, 116t, 119, 145t, 173t, 183t, 254-255  
Cleocin, 93t. *See also* Clindamycin.

clindamycin, 93t, 102t, 116t, 145t, 174t, 209

erythromycin ethylsuccinate, 183t  
erythromycin/sulfisoxazole, 94t, 102t, 116t, 118, 174t, 251,  
254-255  
ethylsuccinate. *See* Erythromycin ethylsuccinate.

FLAVORx in, 118, 189-190

fluconazole, 208

flumist, 236-237

gatifloxacin, 101t  
levofloxacin, 101t  
lorabid, Loracarbef, 92t  
loracarbef, 92t, 115t, 182t  
loracarbef/cefaclor, 101t

Drug names, generic and trade (*continued*)

macrolides, 93t, 102t, 116t, 118, 151, 173t, 183t  
midazolam, 76t  
ofloxacin, 101t  
palivizumab, 234-235  
PCV-7, 13, 17, 23t, 29, 72, 209, 211, 223, 229, 238, 240t-241t,  
243t, 252, 255  
penicillins, 16t, 93t, 101t, 114t, 144t-145t, 146, 172t  
Pneumovax, 161, 252. *See also* PCV-7 (pneumococcal conjugate  
vaccine).  
quinolones, 102t  
RespiGam, 234-235  
reversal agents, 76t  
rifampin, 208  
Rocephin, 93t. *See also* Ceftriaxone.  
RSV injections, 19, 234-235  
sedation and reversal agents, 76t  
Septra/Bactrim, 94t  
sulfamethoxazole. *See* TMP/SMX (timethoprim/  
sulfamethoxazole).  
sulfisoxazole, 183t, 228-229, 232-233. *See also* Erythromycin/  
sulfisoxazole.  
Suprax, 93t. *See also* Cefixime.  
tetracaine, topical, 76t, 77, 82  
TIV, 235-236  
vancomycin, 208  
Zithromax, 93t. *See also* Azithromycin.  
Drug-resistant *Streptococcus pneumoniae* (DRSP), 73  
Dural sinus thrombosis, 224  
Dysfunction mechanisms, ETs, 34-36

Early onset AOM (acute otitis media), 12, 14t  
Early purulent AOM (acute otitis media), color plate 1  
Efficacy measures and predictions, 81-82, 177-189  
for second-line and third-line therapies, 177-189, 178t, 182t-183t  
of tympanocentesis, 81-82  
Elevated lipoprotein apoproteins, 222  
Empyema, subdural, 224  
Enteroviruses, 39t  
Environmental prevention measures, 229-233  
Epidemiology, 19-32  
incidences, 19-22, 21f-22f  
AOM and age, 19-21, 21f-22f  
AOM and ET dysfunction, 19  
AOM and viral URTIs, 19  
overviews of, 19

Epidemiology (*continued*)

risk factors, 21-29, 23t, 26f  
environmental, 21, 23f, 26-29  
genetic, 21-26, 23t, 26f  
overviews of, 21-23, 23t  
Epidural abscesses, 224  
Equipment, tympanocentesis, 74t-75t  
Erythromycin ethylsuccinate, 183t  
Erythromycin/sulfisoxazole, 94t, 102t, 116t, 118, 174t, 251,  
254-255  
Eskola study (Finland), 86-87, 163  
Ethylsuccinate. *See* Erythromycin ethylsuccinate.  
ETs (eustachian tubes), 19, 33-36, 35f  
anatomy of, 33  
dysfunction mechanisms, 19  
dysfunction mechanisms of, 34-36  
function of, 33-34, 35f  
overviews of, 33  
Example case presentations, 251-256  
bilateral purulent conjunctivitis with AOM, 252-253  
lymphadenitis and impetigo development in child with AOM,  
253-254  
overviews of, 251  
persistent AOM, 252-255  
in fully vaccinated child during azithromycin treatment, 255  
in immunized child receiving amoxicillin and with high fever  
and moderate leukocytosis, 252  
persistent vomiting and diarrhea with AOM during amoxicillin  
treatment, 254-255  
pneumonia development in afebrile child with AOM, 251  
Excessive goblet cell numbers, 36-37  
Excessive negative middle ear pressure, 34  
Excessive positive nasopharyngeal pressure, 36  
Excessive tympanosclerosis, 211  
Expected clinical failures, 246t-247t  
Expected complications, 215-221, 217f. *See also* Complications.  
conductive hearing loss, 217f, 218-220  
OME, 215, 217f, 218-220  
overviews of, 215, 217f, 218  
Expected outcomes, 40-42, 44t-45t  
Extradural abscesses, 224  
Extrusion, tympanostomy tubes, 217f, 220  
Facial nerve paralysis, 83  
Factor V Leiden mutations, 222  
Failures, antibiotic therapies, 14t, 15  
FDA (Food and Drug Administration), 15t, 161-169, 236-237

- Feeding, bottle- vs breast-, 27, 231
- Financial-related factors, 113, 114t-117t, 211  
of antibiotic therapies, 113, 114t-117t  
for tympanostomy tubes, 211
- Finnish (Eskola) study, 86-87, 163
- First-line therapies, 141-156. *See also* Antibiotic therapies.  
AAP/AAFP guidelines for, 141-146, 144t-146t  
allergies and, 144t-145t, 151-153, 152f  
antibiotic, 151-153, 152f  
penicillin, 144t-145t  
immune functions and, 153-154  
overviews of, 141-142  
reference resources for, 154-156  
resistant AOM risks and, 142t
- FLAVORx, 118, 189-190
- Floppy tubes, 34
- Fluconazole, 208
- Flumazenil, 76t
- Flumist, 236-237
- Follow-up care, 129-131, 130f, 205  
for antibiotic therapies, 129-131, 130f  
for tympanostomy tubes, 205
- Food and Drug Administration (FDA), 15t, 161-169, 236-237
- Fully vaccinated child during azithromycin treatment (case presentations), 255
- Fundamental concepts, 11-18. *See also* Overviews.  
anatomy fundamentals, local and contiguous structures, 215, 217f  
overviews of, 11-12  
reference resources for, 17  
selection fundamentals, antibiotic therapies, 85-141. *See also*  
Antibiotic therapies.  
terms and abbreviations, 12-13, 14t-16t  
antibiotic failure, 14t  
AOM, 11-17, 14t-16t  
CDC, 14t  
DRSP, 15t  
early onset AOM, 12, 14t  
FDA, 15t  
MEE, 11-17, 15t  
*Moraxella catarrhalis*, 15t  
ntHi, 15t  
OME, 11, 15t  
otitis-prone children, 13, 15t  
PCV-7, 13, 17  
persistent AOM, 12, 14t  
recurrent AOM, 12, 14t  
refractory AOM, 12, 14t  
TM, 11
- Gatifloxacin, 101t
- Gender risk factors, 24
- Generic drug names. *See* Drug names, generic and trade.
- Globlet cell numbers, excessive, 36-37
- Grandenigo's syndrome, 221
- Granulation tissue formation, 210-211
- Group A *Streptococcus*, 37, 55-56, 207
- H1N1 and H3N2 strains, 235-236
- Haemophilus influenzae*, 15t, 37, 42, 55-58, 85-91, 88f, 96-112, 106t-107t, 109f, 146-154, 159-161, 175-176, 187-189, 191-196, 194t, 207
- Haemophilus influenzae* type B (HIB), 154
- Hearing loss, 217-222  
conductive, 217f, 218-220  
permanent profound sensorineural, 217f, 222
- Herd immunity, 163-164
- HIB (*Haemophilus influenzae* type B), 154
- High fever and moderate leukocytosis (case presentation), 252
- HIV (human immunodeficiency virus), 204
- Hydrocephalus, otitic, 221
- Immune functions and antibiotic therapies, 153-154
- Immune responses and allergens, 38-40
- Immunization, 234-245, 252  
bacterial (pneumococcal), 237-245  
active, 238-244  
overviews of, 237-238, 239f, 240t-241t  
passive, 238  
immunized child receiving amoxicillin and with high fever and moderate leukocytosis (case presentation), 252  
viral, 234-237  
active, 235-236  
CAIV, 236-237  
overviews of, 234  
passive, 234-235
- Immunology, 33-46. *See also* Pathophysiology, immunology, and natural history.
- Impetigo and lymphadenitis development in child with AOM (case presentations), 253-254
- Incidences, 19-22, 21f-22f. *See also* Epidemiology.  
AOM and age, 19-21, 21f-22f  
AOM and ET dysfunction, 19  
AOM and viral URTIs, 19
- Ineffective tubal pumping action, 36
- Influenza viruses, 19, 39t
- Intranasal influenza vaccine, cold-adapted, 236-237

Intravenous antibiotics, broad-spectrum, 222

Introductory topics. *See* Fundamental concepts; Overviews.

Invasive disease prevention, 162

Isopropyl alcohol, 76t

Kaiser-Permanente study, 162-163

Kentucky (Block) study, 86-89, 88f, 164, 176-177

Labyrinthitis, 222

Laser myringotomy (LM), 228

Laser-assisted tympanostomy, 204

Less serious uncommon complications, 217f, 220. *See also* Complications.

Leukocytosis and high fever (case presentation), 252

Levofloxacin, 101t

Lighting, pneumatic otoscopy, 65

Linezolid, 209

Lipoprotein apoproteins, elevated, 222

LM (laser myringotomy), 228

Local and contiguous structures, anatomy of, 215, 217f

Lorabid, 92t. *See also* Loracarbef.

Loracarbef, 92t, 115t, 182t

Loracarbef/cefaclor, 101t

Lymphadenitis and impetigo development in child with AOM (case presentations), 253-254

MacArthur Communicative Development Inventory-Words and Sentences tool, 218-219

Macrolides, 93t, 102t, 116t, 118, 151, 173t, 183t

Male gender risk factors, 24

Managed care risk factors, 29

Management and diagnoses of AOM (acute otitis media) topics. *See also under individual topics.*

- antibiotic therapies, 85-203
  - first-line, 141-157
  - second-line and third-line, 157-203
  - selection fundamentals, 85-141
- case presentations, 251-256
- clinical trials. *See* Clinical trials, PCV-7.
- complications, 215-227
- diagnoses, 47-70
- epidemiology, 19-32
- fundamental concepts, 11-18
- pathology, immunology, and natural history, 33-46
- prevention, 227-251
- reference resources for. *See* Reference resources.
- tympanocentesis, 71-84
- tympanostomy tubes, 203-214

Mastoid surgeries, 222

Mastoiditis, 217f, 221-224

Maternal tobacco smoking risk factors, 24-25

Measurement instruments, 218-219

- MacArthur Communicative Development Inventory-Words and Sentences tool, 218-219
- Peabody Developmental Motor Scales, 219

Medicaid program (Tennessee) study, 163-164

MEE (middle ear effusion), 11-17, 15t, 20-21, 53t-54t

- diagnoses of, 53t-54t
- epidemiology of, 20-21
- overviews of, 11-17, 15t
- tympanostomy tubes and, 203

Meningitis, 217f, 221

Microbiology, 39t, 3738. *See also* Pathophysiology, immunology, and natural history.

Midazolam, 76t

Middle ear effusion (MEE), 11-17, 15t, 20-21, 53t-54t

- diagnoses of, 53t-54t
- epidemiology of, 20-21
- overviews of, 11-17, 15t
- tympanostomy tubes and, 203

Middle ear ossicles, 217f, 225

Midface abnormalities, 24

Moderate leukocytosis and high fever (case presentation), 252

*Moraxella catarrhalis*, 15t, 37, 42, 55-58, 85-86, 96-112, 106t-107t, 207

Mortality, general anesthesia-related, 209

*Mycoplasma pneumoniae*, 103, 146

Myringotomy, 222, 227-228

Myringotomy, laser, 228

Names, drugs. *See* Drug names, generic and trade.

Nasopharynx colonization, post-PCV-7, 166-167

National Committee on Clinical Laboratory Standards (NCCLS), 97, 100t-102t

Natural history, 33-46. *See also* Pathophysiology, immunology, and natural history.

NCCLS (National Committee on Clinical Laboratory Standards), 97, 100t-102t

Negative middle ear pressure, excessive, 34

Negative nasopharyngeal pressure, 36

New York (Casey and Pichichero) study, 86, 89, 163-164

Nonbacteriostatic saline, 76t

Noninfected (sterile) MEE (middle ear effusion). *See* OME (otitis media with effusion).

Nontypeable *Haemophilus influenzae* (ntHi), 15t, 37, 42, 106t-107t, 240t-241t, 244  
Norfolk, VA (Caspary) study, 86, 89-90  
NtHi (nontypeable *Haemophilus influenzae*), 15t, 37, 42, 106t-107t, 240t-241t, 244

Office tympanocentesis procedures, 72-77, 74t-75t, 79t-80t.  
*See also* Tympanocentesis.

Ofloxacin, 101t

OME (otitis media with effusion), 11, 15t, 215, 217f, 218-220

Omnicef, 93t. *See also* Cefdinir.

Ossicles, middle ear, 83, 217f, 255

Osteitis, temporal bone, 221

Otitic hydrocephalus, 221

Otitis, adhesive, 220

Otitis media, acute. *See* AOM (acute otitis media) diagnoses and management topics.

Otitis media with effusion (OME), 11, 15t, 215, 217f, 218-220

Otitis-prone children, 13, 15t

Otorrhea management, 128, 206-209  
antibiotic therapies, 128  
tympanostomy tubes and, 206-209

Oto-Scan Laser-Assisted Myringotomy systems, 75t

Otoscopy, pneumatic, 58-65, 59t, 60f-64f  
equipment for, 59t, 64f  
lighting for, 65  
overviews of, 58, 65  
procedures for, 60f-63f  
results interpretation for, 60f-63f

Otowicks, 77

Outcomes, 40-42, 44t-45t, 54-55, 216f  
for antibiotic therapies, 44t-45t, 54-55  
of AOM, 40-42, 44t-45t  
for complications, 216f  
expected, 40-42, 44t-45t

Oval window piercing, 83

Overprescription considerations, 131-133

Overviews. *See also under individual topics.*  
of antibiotic therapies, 85, 141-142, 157, 158t-159t  
first-line, 141-142  
second-line and third-line, 157, 158t-159t  
selection fundamentals, 85  
of case presentations, 251  
of complications, 215, 216f-217f  
of diagnoses, 47-48  
of epidemiology, 19  
of fundamental concepts, 11-12

Overviews (*continued*)  
of pathophysiology, immunology, and natural history, 33  
of prevention, 227  
of tympanocentesis, 71  
of tympanostomy tubes, 203

Oximeters, pulse, 74t

Pacifier use risk factors, 29, 229

Palatability considerations, 114t-117t, 118

Palivizumab, 234-235

Papoose boards, 74t

Paradise diagnostic heads, 63f

Parainfluenza viruses, 39t

Paralysis, facial nerve, 217f, 221-222, 225

Passive immunization, 234-235, 238. *See also* Immunization.  
bacterial, 238  
viral, 234-235

Pathogenesis, 40, 41f. *See also* Pathophysiology, immunology, and natural history.

Pathophysiology, immunology, and natural history, 33-46  
of AOM, 33, 37-42  
allergens and immune responses and, 38-40  
bacteria in, 40  
microbiology of, 37-38, 39t  
outcomes of, 40-42, 44t-45t  
overviews of, 33  
pathogenesis of, 40, 41f  
time course of, 40-42

of ETs, 33-36, 35f  
anatomy of, 33  
dysfunction mechanisms of, 34-36  
function of, 33-34, 35f  
overviews of, 33  
overviews of, 33  
reference resources for, 42-43

Patient compliance, 112-119, 189-190

PCV-7 (pneumococcal conjugate vaccine), 13, 17, 23t, 29, 72, 86-90, 108, 126, 143, 151, 153-154, 160-169, 165f, 168t, 209, 211, 223, 229, 238, 240t-241t, 243t, 244, 252, 255  
clinical trials of, 86-90. *See also* Clinical trials, PCV-7.  
Block study (rural Kentucky), 86-89, 88f  
Casey and Pichichero study (Rochester, NY), 86, 89  
Caspary study (Norfolk, VA), 86, 89-90  
Eskola study (Finland), 86-87

PE (pressure-equalizing tubes), 203-214. *See also* Tympanostomy tubes.

Peabody Developmental Motor Scales, 219

Pediazole, 94t. *See also* Erythromycin/sulfisoxazole.

Penicillins, 16t, 93t, 101t, 114t, 144t-145t, 146, 172t  
 allergies to, 144t-145t, 146  
 PNSP, 85-86, 105, 106t-107t, 111-112, 141-142, 158t,  
 159-161, 169, 187-196, 194t, 209, 223, 232-233, 237-238,  
 239t-241t  
 PSSP, 85-86, 104, 106t-107t, 194t

Perforation, TMs (tympanic membranes), 217f, 220

Permanent profound sensorineural hearing loss, 217f, 222

Persistent AOM (acute otitis media), 215, 217f, 252-255

Persistent vomiting and diarrhea with AOM during amoxicillin treatment (case presentations), 254-255

Petrositis, acute, 222

Pharmaceutical therapies. *See* Antibiotic therapies.

Pharmacokinetics and pharmacodynamics, 177-179, 178t

PIV3 (parainfluenza type 3)-cp45 (cold passage mutant) vaccine, 237

Pneumatic otoscopy, 58-65, 59t, 60f-64f  
 equipment for, 59t, 64f  
 lighting for, 65  
 overviews of, 58, 65  
 procedures for, 60f-63f  
 results interpretation for, 60f-63f

Pneumococcal (bacterial) immunization, 237-245  
 active, 238-244  
 overviews of, 237-238, 239f, 240t-241t  
 passive, 238

Pneumococcal conjugate vaccine (PCV-7), 13, 17, 23t, 29, 72,  
 209, 211, 223, 229, 238, 240t-241t, 243t, 252, 255  
 clinical trials of, 86-90. *See also* Clinical trials, PCV-7.  
 Block study (rural Kentucky), 86-89, 88f  
 Casey and Pichichero study (Rochester, NY), 86, 89  
 Caspary study (Norfolk, VA), 86, 89-90  
 Eskola study (Finland), 86-87

Pneumonia development in afebrile child with AOM (case presentations), 251

PNSP (penicillin-nonsusceptible *Streptococcus pneumoniae*),  
 85-86, 105, 106t-107t, 111-112, 141-142, 158t, 159-161, 169,  
 187-196, 194t, 209, 223, 232-233, 237-238, 239t-241t

Polyclonal RSV-IV-Ig, 234-235

Polysaccharide immunoglobulin, bacterial, 238

Positive nasopharyngeal pressure, excessive, 36

Post-antibiotic AOM (Acute otitis media), 54

Predictors, 57-58. *See also* Diagnoses.  
 causative organism-based, 57-58  
 URTI symptom-based, 57

Presentations (case), 251-256  
 bilateral purulent conjunctivitis with AOM, 252-253  
 lymphadenitis and impetigo development in child with AOM,  
 253-254  
 overviews of, 251  
 persistent AOM, 252, 255  
 in fully vaccinated child during azithromycin treatment, 255  
 in immunized child receiving amoxicillin and with high fever  
 and moderate leukocytosis, 252  
 persistent vomiting and diarrhea with AOM during amoxicillin  
 treatment, 254-255  
 pneumonia development in afebrile child with AOM, 251

Pressure-equalizing (PE) tubes, 203-214. *See also*  
 Tympanostomy tubes.

Prevention, 227-251  
 bacterial (pneumococcal) immunization, 237-245, 238-244  
 active, 238-244  
 overviews of, 237-238, 239f, 240t-241t  
 passive, 238  
 chemoprophylaxis for, 233-234  
 antibiotic, 233-234  
 overviews of, 233  
 xylitol, 233-234  
 environmental measures for, 229-233  
 breast-feeding vs bottle feeding and, 231  
 overviews of, 229-230  
 tobacco smoke exposure and, 231-232  
 URTI pathogen exposure and, 230-231  
 expected clinical failures, 246t-247t  
 overviews of, 227  
 reference resources for, 245, 248-250  
 surgical procedures for, 227-229  
 adenoidectomy, 228-229  
 LM, 228  
 myringotomy, 227-228  
 overviews of, 227  
 tympanostomy tubes, 203-214, 228. *See also* Tympanostomy  
 tubes.  
 viral immunization, 234-237  
 active immunization, 235-236  
 CAIV, 236-237  
 overviews of, 234  
 passive immunization, 234-235

Prevnar, 161, 252. *See also* PCV-7 (pneumococcal conjugate vaccine).

Procedures. *See also under individual topics.*  
 for cultures, 77-81

- Procedures (*continued*)  
 for pneumatic otoscopy, 60f-63f  
 for tympanocentesis  
   equipment for, 74t-75t  
   office tympanocentesis, 72-77, 74t-75t, 79t-80t  
   overviews of, 72  
 for tympanostomy tubes, 209
- Profound sensorineural hearing loss, permanent, 217f, 222
- Prophylaxis, 233-234  
 antibiotic, 232-233  
 chemoprophylaxis, 233-234  
 xylitol, 233-234
- Proteus*, 208
- Prothrombotic disorders, 222
- Proxetil. *See* Cefpodoxime proxetil.
- Pruritic rash, 151
- Pseudomonas*, 208
- PSSP (penicillin-susceptible *Streptococcus pneumoniae*), 85-86,  
 104, 106t-107t, 194t
- Pulse oximeters, 74t
- Pumping action, tubal, 36
- Quinolones, 102t
- Recurrent AOM (acute otitis media), 12, 14t, 215, 217f. *See also*  
 Persistent AOM (Acute otitis media).
- Reference resources. *See also under individual topics.*  
 for antibiotic therapies, 133-140, 154-156, 197-202  
   first-line, 154-156  
   second-line and third-line, 197-202  
   selection fundamentals, 133-140  
 for complications, 225-226  
 for diagnoses, 69-70  
 for fundamental concepts, 17  
 for pathophysiology, immunology, and natural history, 42-43  
 for prevention, 245, 248-250  
 for tympanocentesis, 83  
 for tympanostomy tubes, 212-213
- Refractory AOM (acute otitis media), 12, 14t, 192-199. *See also*  
 Recurrent AOM (acute otitis media).
- Reopening, blocked tubes, 206
- Research studies. *See* Clinical trials, PCV-7.
- Resistant AOM (acute otitis media), 142t
- RespiGam, 234-235
- Respiratory syncytial virus (RSV) injections, 19, 39t, 234-235
- Respiratory tract infections, upper, 19, 39t, 57, 230-231
- Restraints, child, 74t
- Resuscitation equipment, 76t
- Retraction pockets, 210-211
- Reversal agents and sedation, 76t
- Rheumatic fever, 152
- Rifampin, 208
- Risk factors, 21-29, 23t, 26f. *See also under individual topics.*  
 environmental, 21, 23f, 26-29  
 genetic, 21-26, 23t, 26f  
 overviews of, 21-23, 23t  
 tympanocentesis, 71, 73t  
 tympanostomy tubes, 209-211
- Rocephin, 93t. *See also* Ceftriaxone.
- Rochester, NY (Casey and Pichichero) study, 86, 89, 163-164
- Romazicon, 76t
- RSV (respiratory syncytial virus) injections, 19, 39t, 234-235
- Rural Kentucky (Block) study, 86-89, 88f, 164, 176-177
- Safety factors. *See also under individual topics.*  
 antibiotic therapies, 112-113, 189-190  
 tympanocentesis, 82-83
- Sample case presentations, 251-256  
 bilateral purulent conjunctivitis with AOM, 252-253  
 lymphadenitis and impetigo development in child with AOM,  
 253-254  
 overviews of, 251  
 persistent AOM, 252-255  
   in fully vaccinated child during azithromycin treatment, 255  
   in immunized child receiving amoxicillin and with high fever  
   and moderate leukocytosis, 252  
 persistent vomiting and diarrhea with AOM during amoxicillin  
 treatment, 254-255  
 pneumonia development in afebrile child with AOM, 251
- Season-related risk factors, 27
- Second-line and third-line therapies, 157-202. *See also*  
 Antibiotic therapies.  
 AAP/AAFP guidelines for, 157-161, 158t-159t  
 efficacy measures and predictions for, 177-189, 178t, 182t-183t  
 options for, 157-161, 158t-159t  
 overviews of, 157, 158t-159t  
 patient compliance and, 189-190  
 PCV-7, 161-169, 165f, 168t  
 pharmacokinetics and pharmacodynamics for, 177-179, 178t  
 refractory/recurrent AOM and, 192-199  
 safety factors for, 189-190  
 second-line therapies, 169-190  
 selection rationale for, 169  
 success determination for, 170-174, 172t-174t

Second-line and third-line therapies (*continued*)

- third-line therapies, 190-199
- treatment-resistant pathogens and, 175-176
- Sedation and reversal agents, 76t
- Selected references. *See* Reference resources.
- Selection criteria, antibiotic therapies, 85-141. *See also*
  - Antibiotic therapies.
    - additional considerations, 126-132
    - adverse effects, 112-119, 114t-117t
    - algorithms for, 126, 127f
    - choices for, 91-94, 92t-94t, 126, 127f
    - cost-related factors of, 113, 114t-117t
    - dosing frequencies and durations, 91-93, 92t-93t, 114t-117t, 118-126, 121t
    - follow-up care and, 129-131, 130f
    - otorrhea management and, 128
    - overprescription and, 131-133
    - overviews of, 85
    - palatability, 114t-117t, 118
    - patient compliance, 112-119
    - PCV-7, 86-90
    - reference resources for, 133-140
    - safety factors, 112-113
    - susceptibility break points, 101t-102t
    - vaccine serotype replacement, 90-91
    - viruses and, 131
- Sensorineural hearing loss, 209, 217f, 222
- Septra/Bactrim, 94t
- Serious uncommon complications, 217f, 221-225. *See also*
  - Complications.
    - acute petrositis, 222
    - brain abscesses, 224
    - dural sinus thrombosis, 224
    - epidural abscesses, 224
    - extradural abscesses, 224
    - facial nerve paralysis, 217f, 221-222, 225
    - labyrinthitis, 222
    - mastoiditis, 217f, 221-224
    - meningitis, 217f, 221
    - middle ear ossicles, 217f, 225
    - ossicle discontinuity, 217f
    - otitic hydrocephalus, 221
    - overviews of, 221-222
    - permanent profound sensorineural hearing loss, 217f, 222
    - sigmoid sinus thrombosis, 221
    - subdural empyema, 224
    - temporal bone otitis (Gradenigo's syndrome), 221

Serious uncommon complications (*continued*)

- vertigo, 217f, 221, 224
- vs less serious complications, 220
- Serotype replacement, 90-91, 164-165, 165f
- Serous labyrinthitis, 222
- Sibling-related risk factors, 27-28
- Sickle cell disease, 152
- Sigmoid sinus thrombosis, 221
- Sinus thrombosis, 221, 224
  - dural, 224
  - sigmoid, 221
- Socioeconomic status risk factors, 29
- Sof-Spec speculums, 63f
- Staphylococcus aureus*, 146, 207-209
- Sterile (noninfected) MEE (middle ear effusion). *See* OME (otitis media with effusion).
- Streptococcus aureus*, 103, 223
- Streptococcus mutans*, 233-234
- Streptococcus pneumoniae*, 27, 37, 42, 55-58, 72, 85-91, 88f, 95-112, 106t-107t, 109f, 110t, 143, 146-150, 161-169, 175-176, 207, 222-224, 231-238, 239t-240t
- Streptococcus pyogenes*, 57-58, 99
- Studies. *See* Clinical trials, PCV-7.
- Subdural empyema, 224
- Sulfamethoxazole. *See* TMP/SMX (timethoprim/sulfamethoxazole).
- Sulfisoxazole, 183t, 228-229, 232-233
- Summary topics. *See* Fundamental concepts; Overviews.
- Suppurative labyrinthitis, 222
- Suprax, 93t. *See also* Cefixime.
- Surgical procedures, 227-229
  - adenoidectomy, 228-229
  - LM, 228
  - myringotomy, 227-228
  - overviews of, 227
  - typanostomy tubes, 203-214, 228. *See also* Tympanostomy tubes.
- Susceptibility break points, 101t-102t
- Symptoms, 56-57. *See also* Diagnoses.
- Synagis, 234-235
  
- Temporal bone osteitis (Gradenigo's syndrome), 221
- Tennessee Medicaid program study, 163-164
- Terms and abbreviations, 12-13, 14t-16t. *See also under individual topics.*
  - antibiotic failure, 14t
  - AOM, 11-17, 14t-16t
  - CDC, 14t

Terms and abbreviations (*continued*)

DRSP, 15t  
early onset AOM, 12, 14t  
FDA, 15t  
MEE, 11-17, 15t  
*Moraxella catarrhalis*, 15t  
ntHi, 15t  
OME, 11, 15t  
otitis-prone children, 13, 15t  
PCV-7, 13, 17  
persistent AOM, 12, 14t  
recurrent AOM, 12, 14t  
refractory AOM, 12, 14t  
TM, 11  
Tetracaine, topical, 76t, 77, 82  
Third-line therapies, 190-199. *See also* Antibiotic therapies;  
    Second-line and third-line therapies.  
Thrombosis, 221, 224  
    dural sinus, 224  
    sigmoid sinus, 221  
Time course, 40-42  
Timethoprim/sulfamethoxazole (TMP/SMX), 85-86, 94t, 102t,  
    104, 113, 116t, 118, 151, 158t, 174t, 178t, 183t, 185-186,  
    208, 247t, 253  
TIV (trivalent inactivated vaccine), 235-236  
TMP/SMX (timethoprim/sulfamethoxazole), 85-86, 94t, 102t,  
    104, 113, 116t, 118, 151, 158t, 174t, 178t, 183t, 185-186,  
    208, 247t, 253  
TMs (tympanic membranes), color plate 1, 11, 55-56, 56t, 82,  
    217f, 220  
    illustrations of, color plate 1  
    mobility of, 56t  
    normal, color plate 1  
    overviews of, 11  
    perforation, 82, 217f, 220  
    positions of, 55-56, 56t  
Tobacco smoke risk factors, 24-25, 36, 231-232  
Topical tetracaine, 77  
Trade drug names. *See* Drug names, generic and trade.  
Treatment-resistant pathogens, 175-176  
Trivalent inactivated vaccine (TIV), 235-236  
Tuberculin syringes, 75t  
Tubes (tympanostomy), 203-214. *See also* Tympanostomy tubes.  
Tympanic membranes (TMs), color plate 1, 11, 55-56, 56t, 82,  
    217f, 220  
    illustrations of, color plate 1  
    mobility of, 56t

Tympanic membranes (TMs) (*continued*)

normal, color plate 1  
overviews of, 11  
perforation, 82, 217f, 220  
positions of, 55-56, 56t  
Tympanocentesis, 71-84  
    AAP/AAFP guidelines for, 71-72, 73t-76t, 81-82  
    antibiotic therapies and, 196. *See also* Antibiotic therapies.  
    second-line and third-line therapies, 196  
    benefits vs risks of, 71, 73t  
    efficacy of, 81-82  
    overviews of, 71  
    procedures for, 72-81, 73t-76t, 78f-80f  
        culture procedures, 77-81  
        equipment for, 74t-75t  
        office tympanocentesis, 72-77, 74t-75t, 79t-80t  
    overviews of, 72  
    rationale for, 71-72, 73t-76t  
    reference resources for, 83  
    safety of, 82-83  
    tympanostomy tubes and, 203-214. *See also* Tympanostomy  
        tubes.  
Tympanosclerosis, 209-210, 217f, 220  
Tympanostomy tubes, 203-214  
    care of, 204-206  
        blocked tube reopening, 206  
        overviews of, 204  
        physician follow-up care, 205  
        water exposure, 205  
    cost of, 211  
    criteria for, 203-204  
    efficacy of, 211-212  
        overviews of, 211-212  
        vs antibiotic prophylaxis, 212  
        vs placebo, 212  
    laser-assisted tympanostomy, 204  
    otorrhea and, 206-209  
        as AOM sign, 207-208  
        as normal sequela, 206-207  
        overviews of, 206  
    overviews of, 203  
    reference resources for, 212-213  
    risks of, 209-211  
        cholesteatoma, 210-211  
        complications, 209-211  
        extrusion, 217f, 220  
        mortality, general anesthesia-related, 209

Tympanostomy tubes, risks of (*continued*)  
  overviews of, 209  
  procedure-related risks, 209  
  retraction pockets, 210-211  
  sensorineural hearing loss, 209  
  tympanosclerosis, 209-210  
  tympanocentesis and, 71-84. *See also* Tympanocentesis.  
Tymp-Tap, 75t, 77

Uncommon complications, 217f, 220-225. *See also*  
  Complications.  
  less serious, 217f, 220  
  serious, 217f, 221-225

Urticaria, 151

URTIs (upper respiratory tract infections), 19, 39t, 57, 230-231

Vaccinated child during azithromycin treatment (case  
  presentations), 255

Vaccine serotype replacement, 90-91

Vancomycin, 208

Vantin, 93t. *See also* Cefpodoxime proxetil.

Versed, 76t

Vertigo, 217f, 221, 224

Viral immunization, 234-237  
  active immunization, 235-236  
  CAIV, 236-237  
  overviews of, 234  
  passive immunization, 234-235

Virginia (Caspar) study, 86, 89-90

Viruses, 39t

Vomiting and diarrhea with AOM during amoxicillin treatment  
  (case presentations), 254-255

Water exposure, 205

White race as risk factor, 25

Wymox, 92t. *See also* Amoxicillin.

Xylitol prophylaxis, 233-234

Zithromax, 92t, 93t. *See also* Azithromycin.